PhaseBio Pharmaceuticals Inc Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Balance sheets

In millions of USD, except per-share amounts

	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018
Assets
Current assets:
Cash and cash equivalents
Restricted cash
Other receivables
Receivable from sublicense
Prepaid expenses and other assets
Total current assets
Property and equipment, net
Deferred offering costs
Operating lease right-of-use assets
Other assets
Total assets

Liabilities and stockholders' deficit
Current liabilities:
Current portion of long-term debt
Current portion of deferred sublicense revenue
Accounts payable
Accrued expenses and other current liabilities
Total current liabilities
Preferred stock warrant liability
Long-term debt, net
Operating lease liabilities, net
Long-term portion of deferred sublicense revenue
Development derivative liability
Other long-term liabilities
Deferred rent
Total liabilities
Redeemable convertible preferred stock, $0.001 par value; zero and 13,321,350 shares authorized at December 31, 2018 and 2017, respectively; zero and 9,131,999 shares issued and outstanding at December 31, 2018 and 2017, respectively.
Stockholders’ deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding at June 30, 2022 and December 31, 2021
Common stock, $0.001 par value; 200,000,000 shares authorized; 49,888,083 shares issued and 49,858,116 shares outstanding at June 30, 2022; 48,220,557 shares issued and 48,190,590 shares outstanding at December 31, 2021
Treasury stock, at cost, 29,967 shares as of March 31, 2022 and December 31, 2021
Treasury stock, at cost, 29,967 shares as of June 30, 2022 and December 31, 2021
Additional paid-in capital
Accumulated deficit
Total stockholders’ deficit
Total liabilities and stockholders' deficit

Comments